Loading...
•
Dec 31, 2024
Ultralife Q4 2024 Earnings Report
Ultralife reported a slight revenue decline and reduced profitability in Q4 2024, impacted by acquisition costs and a significant drop in Communications Systems sales.
Key Takeaways
Ultralife Corporation posted Q4 2024 revenue of $43.9 million, down slightly year-over-year. Profitability metrics, including net income and operating income, decreased, largely due to one-time costs related to the Electrochem acquisition and a sharp decline in Communications Systems revenue. Adjusted EBITDA and gross margin also declined compared to the prior year.
Revenue was $43.9 million, including $6.1 million from Electrochem.
Net income dropped to $194,000, with diluted EPS at $0.01.
Adjusted EBITDA declined to $3.9 million from $4.8 million last year.
Communications Systems revenue fell 55.1% to $4.0 million.
Revenue by Segment
Forward Guidance
Ultralife expects profitable growth in 2025 driven by backlog strength, product launches, and integration synergies from Electrochem.
Positive Outlook
- Entered 2025 with a $102.2 million backlog and high-confidence orders.
- New products scheduled to launch in high-growth markets.
- Integration of Electrochem expected to deliver cost efficiencies.
- Strengthened sales and marketing team to drive organic growth.
- Vertical integration to yield U.S.-based savings.
Challenges Ahead
- Fulfillment delays pushed orders into 2025, impacting Q4 revenue.
- Short-term financial fluctuations due to order timing.
- One-time acquisition costs pressured operating income.
- Lower medical battery and industrial sales dragged segment performance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...